THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Clinical trials for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) explained in plain language.
Never miss a new study
Get alerted when new THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF) trials appear
Sign up with your email to follow new studies for THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Last-Chance drug access for serious illnesses
Disease control AVAILABLEThis program provides access to the drug ruxolitinib for patients with serious conditions like certain blood cancers and severe graft-versus-host disease. It is for people who have no other treatment options and cannot join a standard clinical trial. The program allows doctors to…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Massive 5,000-Person study launches to map the journey of rare blood cancers
Knowledge-focused Recruiting nowThis is a long-term observational study designed to better understand a group of rare, chronic blood cancers called myeloproliferative neoplasms (MPNs). It will follow 5,000 adults in the U.S. for 5-10 years, collecting health records and patient surveys to track symptoms, treatm…
Matched conditions: THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC